SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — John Henry Holliday Synthetic CCD

PatientJohn Henry Holliday
Date of birth2004-08-14
IdentifiersMRN HR-NI007-SYN; SSN (made up) 000-07-8153
Document date2026-11-01
AuthorMartin Beaumont, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Diagnosis of cavitary pulmonary tuberculosis: sputum, chest X-ray, baseline tests, public-health report, home isolation, and alcohol assessment with a safety assessment. Concerns: He wants to get back to his dental practice as soon as it is safe for his patients; He is frightened by the diagnosis and wants to know that it can be cured. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Rifampin 300 mg capsules, two capsules (600 mg) daily600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phaseOral route2026-02-12 to 2026-04-08completedS
Ethambutol 400 mg tablets, three tablets (1200 mg) daily1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results returnOral route2026-02-12 to 2026-03-10stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-02-12 to 2026-08-13completedS

Procedures

ProcedureDatesStatusEvidence
Chest X-ray, two views: right upper lobe consolidation with a 3 cm thick-walled cavity; no effusion or hilar enlargement2026-02-10 to 2026-02-10completedS
Chest X-ray, two views, at the end of treatment: cavity closed, with residual right upper lobe scarring; kept as the baseline for any future comparison2026-08-18 to 2026-08-18completedS

Immunizations

DateVaccineStatusEvidence
2022-08-30Tetanus, diphtheria, and pertussis (Tdap) boostercompletedS
2026-09-22Influenza vaccine, 2026-2027 seasoncompletedS
2026-09-22Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1872Developed a bad cough shortly after beginning to practice dentistryD (CLM-0004)

Family History

RelativeConditionAge at deathEvidence
motherPulmonary tuberculosis; died of it in 1866D (CLM-0002)

Health Concerns

ConcernStatusEvidence
He wants to get back to his dental practice as soon as it is safe for his patientsactiveS
He is frightened by the diagnosis and wants to know that it can be curedactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.4 on 2026-08-18; Leukocytes [#/volume] in Blood by Automated count 9.4 on 2026-02-10; Platelets [#/volume] in Blood by Automated count 412 on 2026-02-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 64 on 2026-05-19; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 58 on 2026-05-19; Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 on 2026-05-19; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 98 on 2026-05-19; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 78 on 2026-02-10; Albumin [Mass/volume] in Serum or Plasma 3.4 on 2026-02-10; Creatinine [Mass/volume] in Serum or Plasma 0.86 on 2026-02-10; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 124 on 2026-02-10; Glucose [Mass/volume] in Serum or Plasma 90 on 2026-02-10; Hemoglobin A1c/Hemoglobin.total in Blood 5.2 on 2026-02-10; Visual acuity uncorrected Right eye by ETDRS eye chart 85 on 2026-02-24; Visual acuity uncorrected Left eye by ETDRS eye chart 84 on 2026-02-24; Total score [AUDIT] 15 on 2026-02-10; Total score [AUDIT-C] 3 on 2026-09-22; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-08-18; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-22 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic.
Alcohol use disorder, mild, with binge drinkingactiveconfirmed F10.10S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic.
Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolvedresolvedconfirmed A08.4S — Synthetic intercurrent illness chosen to teach the assessment of nausea on isoniazid and rifampin; it does not echo a documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-10Hemoglobin [Mass/volume] in Blood12.6g/dL13.2-16.6 g/dLLowS
2026-02-10Leukocytes [#/volume] in Blood by Automated count9.410*3/uL4-11 10*3/uLNormalS
2026-02-10Platelets [#/volume] in Blood by Automated count41210*3/uL150-400 10*3/uLHighS
2026-02-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L7-56 U/LNormalS
2026-02-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L10-40 U/LNormalS
2026-02-10Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-02-10Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma92U/L40-129 U/LNormalS
2026-02-10Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma78U/L8-61 U/LHighS
2026-02-10Albumin [Mass/volume] in Serum or Plasma3.4g/dL3.5-5 g/dLLowS
2026-02-10Creatinine [Mass/volume] in Serum or Plasma0.86mg/dL0.74-1.35 mg/dLNormalS
2026-02-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M124mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-02-10Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
2026-02-10Hemoglobin A1c/Hemoglobin.total in Blood5.2%<=5.6%NormalS
2026-02-10Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
2026-02-10Visual acuity uncorrected Left eye by ETDRS eye chart85{letters}>=80NormalS
2026-02-10Total score [AUDIT]15{score}S
2026-02-10Total score [AUDIT-C]9{score}S
2026-02-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-02-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L7-56 U/LNormalS
2026-02-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma39U/L10-40 U/LNormalS
2026-02-24Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-02-24Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
2026-02-24Visual acuity uncorrected Left eye by ETDRS eye chart84{letters}>=80NormalS
2026-02-24Total score [AUDIT-C]4{score}S
2026-03-17Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma52U/L7-56 U/LNormalS
2026-03-17Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma47U/L10-40 U/LHighS
2026-03-17Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
2026-03-17Total score [AUDIT-C]2{score}S
2026-04-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L7-56 U/LNormalS
2026-04-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma35U/L10-40 U/LNormalS
2026-04-14Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-04-14Total score [AUDIT-C]1{score}S
2026-08-18Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-56 U/LNormalS
2026-08-18Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L10-40 U/LNormalS
2026-08-18Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-08-18Hemoglobin [Mass/volume] in Blood14.4g/dL13.2-16.6 g/dLNormalS
2026-08-18Total score [AUDIT-C]3{score}S
2026-08-18Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-05-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma64U/L7-56 U/LHighS
2026-05-19Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma58U/L10-40 U/LHighS
2026-05-19Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.1-1.2 mg/dLNormalS
2026-05-19Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma98U/L40-129 U/LNormalS
2026-05-19Total score [AUDIT-C]4{score}S
2026-09-22Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-09-22Total score [AUDIT-C]3{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-02-10Body height178cmS
2026-02-10Body weight58kgS
2026-02-10Body mass index (BMI) [Ratio]18.3kg/m2S
2026-02-10Systolic blood pressure112mm[Hg]S
2026-02-10Diastolic blood pressure70mm[Hg]S
2026-02-10Heart rate104/minS
2026-02-10Respiratory rate20/minS
2026-02-10Body temperature37.8CelS
2026-02-10Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-02-24Body height178cmS
2026-02-24Body weight59kgS
2026-02-24Body mass index (BMI) [Ratio]18.6kg/m2S
2026-02-24Systolic blood pressure114mm[Hg]S
2026-02-24Diastolic blood pressure72mm[Hg]S
2026-02-24Heart rate92/minS
2026-02-24Respiratory rate18/minS
2026-02-24Body temperature37.3CelS
2026-02-24Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-03-17Body height178cmS
2026-03-17Body weight61kgS
2026-03-17Body mass index (BMI) [Ratio]19.3kg/m2S
2026-03-17Systolic blood pressure116mm[Hg]S
2026-03-17Diastolic blood pressure72mm[Hg]S
2026-03-17Heart rate84/minS
2026-03-17Respiratory rate16/minS
2026-03-17Body temperature36.8CelS
2026-03-17Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-04-14Body height178cmS
2026-04-14Body weight62.5kgS
2026-04-14Body mass index (BMI) [Ratio]19.7kg/m2S
2026-04-14Systolic blood pressure116mm[Hg]S
2026-04-14Diastolic blood pressure74mm[Hg]S
2026-04-14Heart rate78/minS
2026-04-14Respiratory rate16/minS
2026-04-14Body temperature36.7CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-18Body height178cmS
2026-08-18Body weight65.5kgS
2026-08-18Body mass index (BMI) [Ratio]20.7kg/m2S
2026-08-18Systolic blood pressure118mm[Hg]S
2026-08-18Diastolic blood pressure74mm[Hg]S
2026-08-18Heart rate72/minS
2026-08-18Respiratory rate14/minS
2026-08-18Body temperature36.6CelS
2026-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-05-19Body height178cmS
2026-05-19Body weight61.8kgS
2026-05-19Body mass index (BMI) [Ratio]19.5kg/m2S
2026-05-19Systolic blood pressure108mm[Hg]S
2026-05-19Diastolic blood pressure68mm[Hg]S
2026-05-19Heart rate98/minS
2026-05-19Respiratory rate16/minS
2026-05-19Body temperature37.4CelS
2026-05-19Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-22Body height178cmS
2026-09-22Body weight66kgS
2026-09-22Body mass index (BMI) [Ratio]20.8kg/m2S
2026-09-22Systolic blood pressure118mm[Hg]S
2026-09-22Diastolic blood pressure72mm[Hg]S
2026-09-22Heart rate68/minS
2026-09-22Respiratory rate14/minS
2026-09-22Body temperature36.6CelS
2026-09-22Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-02-10Diagnosis of cavitary pulmonary tuberculosis: sputum, chest X-ray, baseline tests, public-health report, home isolation, and alcohol assessment with a safety assessmentfinishedS
2026-02-24Two-week follow-up on treatment with infectious diseases consultationfinishedS
2026-03-17Five-week review: susceptibility results, release from isolation, and liver monitoringfinishedS
2026-04-14End of the intensive phase: two-month sputum and the start of the continuation phasefinishedS
2026-08-18End-of-treatment review after six monthsfinishedS
2026-05-19Same-day sick visit for nausea and vomiting during tuberculosis treatmentfinishedS
2026-09-22Adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Infectious diseases consultation to confirm the regimen and plan monitoring for cavitary pulmonary tuberculosis in a man who drinks heavilycompletedGL-ATS-TB-2016, GL-ATS-TB-2025S
Standard treatment: isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks, by video-observed therapy with the health department, with pyridoxinecompletedGL-ATS-TB-2016S
Monitoring: monthly symptom and weight check, sputum smear and culture monthly until two consecutive cultures are negative, liver tests at two weeks and monthly because of alcohol, and vision checks while on ethambutolcompletedGL-ATS-TB-2016, GL-ATS-HEPATOTOX-2006S
Public health: same-day report to the local health department, home isolation until noninfectious, and a contact investigation of his household, coworkers, and patients led by the health departmentcompletedGL-CDC-CONTACT-2005, GL-ATS-TB-2016S
Alcohol care: brief intervention at diagnosis, a goal of no alcohol during treatment, counseling with a substance-use counselor, medication offered, AUDIT-C at each visit, and a safety review with the 988 Suicide & Crisis Lifeline at every visitcompletedGL-USPSTF-ALC-2018, GL-SUD-2021, GL-SUICIDE-2024S

Goals

GoalTargetStatusOutcomeProvenance
Complete 182 doses of treatment under video-observed therapy within six months2026-08-18completedAll 182 doses completed: 56 in the intensive phase and 126 in the continuation phase, with one dose held during a stomach illness and made up at the endS
Sputum culture negative at two months2026-08-18completedTwo-month culture showed no growth, so the continuation phase stayed at four monthsS
No alcohol during treatment, to protect his liver2026-08-18activeNot fully met: no drinking for most of the six months, with one evening of heavy drinking at a party about three months into treatment; AUDIT-C 3 at the endS
Return to work once he is no longer infectious2026-03-17completedReleased from home isolation after three negative sputum smears and back at work four weeks into treatmentS
Weight back to at least 64 kg by the end of treatment2026-08-18completed65.5 kg at the end of treatment, from 58.0 kg at diagnosisS

Functional Status

Mental Status

Structured synthetic safety assessment on 2026-02-10: current ideation absent, intent absent, plan absent. Routine outpatient care. A new serious diagnosis, isolation, and heavy drinking can raise suicide risk, so safety is reviewed at every visit. He saved the 988 Suicide & Crisis Lifeline in his phone. No firearm in the home [S]